Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Top-Line Results For Sanofi/Genzyme's MS Drug Lemtrada Leave Investors Wanting More

This article was originally published in The Pink Sheet Daily

Executive Summary

Alemtuzumab scores a win in reducing relapse rates, but doesn't best interferon beta-1a at preventing disability in first of two crucial Phase III studies due to report this year.

You may also be interested in...



Sanofi/Genzyme MS Drug Lemtrada Scores High Against Rebif

Genzyme, a Sanofi company, set the bar high for its multiple sclerosis contender by stacking it up against Roche’s interferon beta-1a in Phase III trials and got the results it was looking for, with a filing set for this quarter.

Sanofi/Genzyme MS Drug Lemtrada Scores High Against Rebif

Genzyme, a Sanofi company, set the bar high for its multiple sclerosis contender by stacking it up against Roche’s interferon beta-1a in Phase III trials and got the results it was looking for, with a filing set for this quarter.

Biogen Idec’s BG-12 Results Up The Ante In The Oral MS Market

The competitive profile of Biogen Idec Inc.’s BG-12 in the highly coveted and burgeoning market for oral multiple sclerosis drugs got a big boost April 21 with the release of better-than-expected additional monotherapy data from the Phase III DEFINE study.

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel